These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25936384)

  • 1. Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):1005-20. PubMed ID: 25936384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A compounding agent of alogliptin and pioglitazone].
    Ueki K
    Nihon Rinsho; 2011 May; 69(5):877-82. PubMed ID: 21595275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Eur J Pharmacol; 2009 Jan; 602(2-3):448-54. PubMed ID: 19038243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
    J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
    Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
    Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
    Ndefo UA; Okoli O; Erowele G
    Am J Health Syst Pharm; 2014 Jan; 71(2):103-9. PubMed ID: 24375601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.
    Karim A; Laurent A; Munsaka M; Wann E; Fleck P; Mekki Q
    J Clin Pharmacol; 2009 Oct; 49(10):1210-9. PubMed ID: 19622714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Br J Pharmacol; 2009 Jun; 157(3):415-26. PubMed ID: 19371350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.
    Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
    Clin Exp Pharmacol Physiol; 2015 Dec; 42(12):1225-38. PubMed ID: 26218204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
    Triplitt C; Cersosimo E; DeFronzo RA
    Vasc Health Risk Manag; 2010 Sep; 6():671-90. PubMed ID: 20859539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alogliptin benzoate for management of type 2 diabetes.
    Saisho Y
    Vasc Health Risk Manag; 2015; 11():229-43. PubMed ID: 25914541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alogliptin benzoate for the treatment of type 2 diabetes.
    Rendell M; Drincic A; Andukuri R
    Expert Opin Pharmacother; 2012 Mar; 13(4):553-63. PubMed ID: 22296609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Pratley RE; Reusch JE; Fleck PR; Wilson CA; Mekki Q;
    Curr Med Res Opin; 2009 Oct; 25(10):2361-71. PubMed ID: 19650752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
    Bailey CJ; Green BD; Flatt PR
    Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
    Jarvis CI; Cabrera A; Charron D
    Ann Pharmacother; 2013 Nov; 47(11):1532-9. PubMed ID: 24285765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.
    Kaku K; Itayasu T; Hiroi S; Hirayama M; Seino Y
    Diabetes Obes Metab; 2011 Nov; 13(11):1028-35. PubMed ID: 21682833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
    Bosi E; Ellis GC; Wilson CA; Fleck PR
    Diabetes Obes Metab; 2011 Dec; 13(12):1088-96. PubMed ID: 21733058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats.
    Cummings BP; Bettaieb A; Graham JL; Stanhope K; Haj FG; Havel PJ
    J Endocrinol; 2014 Apr; 221(1):133-44. PubMed ID: 24627447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alogliptin: a review of its use in patients with type 2 diabetes mellitus.
    Keating GM
    Drugs; 2015 May; 75(7):777-96. PubMed ID: 25855222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
    Scheen AJ
    Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.